Avandia Revenues Sink Under Safety Attack
This article was originally published in The Pink Sheet Daily
Executive Summary
Sales of rosiglitazone were hit the hardest in the U.S., falling 31 percent, GSK reports days ahead of an FDA advisory committee meeting.